Compare Alcon AG (ALC) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Jones Lang LaSalle Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Jones Lang LaSalle Inc trades at $325.01 (market cap $15.43B). The key difference: Alcon AG is far larger — about 2.1× Jones Lang LaSalle Inc's market cap, and Alcon AG pays a 0.54% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.
| ALC | JLL | |
|---|---|---|
Market Cap | $32.69B | $15.43B |
Sector | Health | Real Estate |
52-Week High | $92.22 | $358.66 |
52-Week Low | $62.02 | $248.95 |
Enterprise Value | $36.28B | $18.97B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
JLL trades at $332.57, up 1.56% today, with a bullish technical outlook and strong earnings momentum after beating Q1 2026 EPS estimates. Revenue grew to $26.12B in 2025, with net income reaching $792.10M and improving margins. Positive analyst sentiment includes a $405.50 consensus price target, and recent news highlights strategic growth initiatives and inclusion on Zacks Strong Buy lists as of June 2026.
The stock presents a favorable risk-reward profile with a 22% upside to the consensus target, supported by robust cash flow generation and debt reduction. Key risks include economic sensitivity and competitive pressures, but institutional backing and consistent earnings beats underpin a constructive outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
